Literature DB >> 33361782

SGLT2 inhibitors may offer benefit beyond diabetes.

Amy Kang1,2, Meg J Jardine3,4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33361782     DOI： 10.1038/s41581-020-00391-2

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  1 in total

1.  Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF).

Authors:  Pardeep S Jhund; Mark C Petrie; Naveed Sattar; Matthew M Y Lee; Katriona J M Brooksbank; Kirsty Wetherall; Kenneth Mangion; Giles Roditi; Ross T Campbell; Colin Berry; Victor Chong; Liz Coyle; Kieran F Docherty; John G Dreisbach; Catherine Labinjoh; Ninian N Lang; Vera Lennie; Alex McConnachie; Clare L Murphy; Colin J Petrie; John R Petrie; Iain A Speirits; Steven Sourbron; Paul Welsh; Rosemary Woodward; Aleksandra Radjenovic; Patrick B Mark; John J V McMurray
Journal:  Circulation       Date:  2020-11-13       Impact factor: 39.918
  1 in total
  9 in total

Review 1.  Key metalloproteinase-mediated pathways in the kidney.

Authors:  Tammo Ostendorf; Andreas Ludwig; Justyna Wozniak; Jürgen Floege
Journal:  Nat Rev Nephrol       Date:  2021-04-20       Impact factor: 28.314

Review 2.  Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations.

Authors:  Heidi Noels; Michael Lehrke; Raymond Vanholder; Joachim Jankowski
Journal:  Nat Rev Nephrol       Date:  2021-05-10       Impact factor: 28.314

Review 3.  Association of metabolic dysfunction-associated fatty liver disease with kidney disease.

Authors:  Ting-Yao Wang; Rui-Fang Wang; Zhi-Ying Bu; Giovanni Targher; Christopher D Byrne; Dan-Qin Sun; Ming-Hua Zheng
Journal:  Nat Rev Nephrol       Date:  2022-01-10       Impact factor: 28.314

Review 4.  Role of Erythropoiesis-Stimulating Agents in Cardiovascular Protection in CKD Patients: Reappraisal of Their Impact and Mechanisms.

Authors:  Tetsuji Miura; Tatsuya Sato; Toshiyuki Yano; Akira Takaguri; Takayuki Miki; Noritsugu Tohse; Keitaro Nishizawa
Journal:  Cardiovasc Drugs Ther       Date:  2022-02-12       Impact factor: 3.727

5.  Canagliflozin Ameliorates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism and Inhibiting Inflammation through Induction of Autophagy.

Authors:  Zhipeng Xu; Wenxin Hu; Bin Wang; Ting Xu; Jianning Wang; Dan Wei
Journal:  Yonsei Med J       Date:  2022-07       Impact factor: 3.052

Review 6.  Value of SGLT-2 inhibitors in the treatment of chronic kidney disease : Clinical and practical implications.

Authors:  Marcus Säemann; Daniel Cejka; Sabine Schmaldienst; Alexander R Rosenkranz; Gert Mayer
Journal:  Wien Klin Wochenschr       Date:  2022-10-17       Impact factor: 2.275

7.  Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor.

Authors:  Katherine R Tuttle
Journal:  Clin J Am Soc Nephrol       Date:  2022-04-28       Impact factor: 10.614

Review 8.  SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.

Authors:  Xiaodan Wang; Jingyu Ni; Rui Guo; Lan Li; Jing Su; Feng He; Guanwei Fan
Journal:  Heart Fail Rev       Date:  2021-03-12       Impact factor: 4.214

Review 9.  An Overview of the Cardiorenal Protective Mechanisms of SGLT2 Inhibitors.

Authors:  Teresa Salvatore; Raffaele Galiero; Alfredo Caturano; Luca Rinaldi; Anna Di Martino; Gaetana Albanese; Jessica Di Salvo; Raffaella Epifani; Raffaele Marfella; Giovanni Docimo; Miriam Lettieri; Celestino Sardu; Ferdinando Carlo Sasso
Journal:  Int J Mol Sci       Date:  2022-03-26       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.